Survodutide Weight Loss Drug: Phase 3 Results, FDA Status & What to Do Now

The bottom line on the survodutide weight loss drug

The survodutide weight loss drug is an investigational once-weekly injection from Boehringer Ingelheim that hit up to an average of 16.6% weight loss at 76 weeks in its Phase 3 SYNCHRONIZE-1 trial — topline results released April 28, 2026. The molecule is real. The prescription path is not.

Survodutide is not FDA approved. You can't legitimately buy it from any pharmacy, telehealth provider, or “research peptide” site. Boehringer has guided toward a 2027 or 2028 launch contingent on favorable trial data — but no FDA submission, approval date, launch date, or price is confirmed today.

Quick status — survodutide at a glance

Survodutide current status at a glance — Phase 3 topline results released April 28, 2026.

What is the survodutide weight loss drug?

If you've taken Wegovy or Ozempic, you know GLP-1 (glucagon-like peptide-1) — that's the receptor that tells your brain you're full and slows your stomach down. Survodutide does that. But it also activates a second receptor: glucagon. Most people associate glucagon with raising blood sugar in an emergency. What's less famous is its role in energy expenditure and liver fat metabolism.

That dual-mechanism design is why this drug exists and why people care. It's also why the “BI 456906” name keeps showing up in older trial papers and on Reddit. Boehringer hasn't picked a brand name yet — that comes around approval.

Who actually makes it?

Survodutide was originally invented at Zealand Pharma in Denmark and licensed to Boehringer Ingelheim, which now runs all global development and commercialization. Zealand keeps co-promotion rights in the Nordic countries and gets royalties from sales if the drug launches. The most authoritative pages are boehringer-ingelheim.com and zealandpharma.com — not the dozens of “buy survodutide online” sites flooding search results. Neither company has partnered with any U.S. pharmacy, telehealth platform, or compounding pharmacy to distribute the drug, because there's nothing to distribute.

What did Phase 3 actually show? (The numbers Boehringer released April 28, 2026)

Sources: Boehringer Ingelheim press release, April 28, 2026; Zealand Pharma announcement, April 28, 2026; Reuters and BioPharma Dive coverage, April 28, 2026; The Wall Street Journal coverage of fat-vs-muscle composition, April 28, 2026.

A note on estimands (why the topline number has a footnote)

Boehringer reported results under two statistical frameworks: the efficacy estimand (treatment effect if everyone stayed on therapy as planned) and the treatment-regimen estimand (treatment effect regardless of adherence). The 16.6% headline figure used the efficacy estimand. Both estimands met both co-primary endpoints. The full breakdown will land at ADA in June.

Why Phase 3 (16.6%) is lower than Phase 2 (18.7%)

Survodutide's Phase 2 obesity trial showed up to 18.7% weight loss at 46 weeks. The Phase 3 trial is bigger, longer, and used a gentler titration — different statistical framing, larger and more diverse population, and 30 more weeks of follow-up that include people who hit a plateau. Cross-phase number comparisons aren't apples-to-apples. The 16.6% number is the one Boehringer will show the FDA.

What the topline release didn't tell us

• Responder breakdowns at ≥10%, ≥15%, ≥20%, or ≥25%
• Full safety table — actual nausea/vomiting/diarrhea rates, serious adverse event rates, discontinuation rates by dose
• Subgroup analyses (sex, age, BMI, race, baseline metabolic risk)
• Body composition detail beyond “predominantly fat”
• Cardiovascular signals (those come from SYNCHRONIZE-CVOT, which is years away)

The full SYNCHRONIZE-1 dataset will be presented at the American Diabetes Association Scientific Sessions, June 5–8, 2026. Expect updated coverage from The RX Index within 24 hours of the presentation.

How survodutide stacks up against other GLP-1s

Cross-trial comparisons are not head-to-head trials. Different populations, baselines, statistical methods, and durations make a 16.6% in one trial not directly equivalent to a 20.9% in another. With that caveat front and center:

Sources: Boehringer Ingelheim April 28, 2026 release; Le Roux et al., Lancet Diab Endocrinol 2024; Jastreboff et al., NEJM 2022 (SURMOUNT-1); Aronne et al., NEJM 2025 (SURMOUNT-5); Wilding et al., NEJM 2021 (STEP 1); Novo Nordisk March 19, 2026 release (STEP UP / Wegovy HD); FDA Foundayo prescribing information; Jastreboff et al., NEJM 2023 (retatrutide Phase 2).

Is the survodutide weight loss drug FDA approved?

The realistic survodutide approval timeline

What still has to happen between today and approval

1. Phase 3 obesity program completion. SYNCHRONIZE-1 read out April 28, 2026. SYNCHRONIZE-2 (obesity with type 2 diabetes) is the second pillar and hasn't read out yet.
2. Full data package. ADA presentation in June, journal publication, and the all-enrollees / sensitivity analyses.
3. NDA filing. Boehringer hasn't publicly committed to a date.
4. FDA acceptance and review. The FDA has 60 days to accept the NDA, then a standard review of ~10 months for a novel mechanism. Sometimes longer.
5. Possible advisory committee. New mechanisms often get a public advisory committee meeting.
6. Labeling negotiation, manufacturing inspections, REMS decisions.
7. Post-approval launch. Pricing decisions, payer negotiations, distribution buildout.

If everything moves crisply, late 2027. If there's an advisory committee or a CMC follow-up, 2028. Boehringer's own public guidance has stayed inside that window.

Can you buy the survodutide weight loss drug today?

Why “buy survodutide online today” is a bad idea (in five reasons)

How do I find a survodutide clinical trial?

Go to ClinicalTrials.gov and search for “survodutide” or “BI 456906”. Filter by Status: “Recruiting” or “Not yet recruiting”; Country: United States; Condition: obesity, MASH, or type 2 diabetes.

• NCT06066528 (SYNCHRONIZE-2) — obesity with type 2 diabetes
• NCT06745284 — head-to-head survodutide vs semaglutide for energy expenditure (Phase 1)
• LIVERAGE / LIVERAGE-Cirrhosis — MASH and MASH cirrhosis (~1,800 participants combined)
• SYNCHRONIZE-CVOT — cardiovascular outcomes in obesity with elevated CV risk

Questions to ask before enrolling

1. Will I receive placebo? What's the randomization ratio?
2. How long is the trial, and what happens after? (Some trials offer extension access; many don't.)
3. What are the visit and lab requirements?
4. Are medication, visits, labs, and travel covered?
5. What side effects should trigger urgent contact, and who do I call?
6. Can I switch to approved treatment if I'm not satisfied?
7. What's the trial site's track record?

If you're trial-curious, talk to your primary care clinician or an obesity-medicine specialist before you enroll.

Survodutide vs Wegovy, Wegovy HD, Zepbound, Mounjaro & retatrutide

The cleanest comparison today is by status and mechanism, not headline percentage. There are no head-to-head trials proving survodutide is better than any of them.

Survodutide vs Wegovy (semaglutide 2.4 mg)

Mechanism: Survodutide is GLP-1 + glucagon. Wegovy 2.4 mg is GLP-1 only. Phase 3 weight loss: Survodutide 16.6% vs Wegovy 14.9% (STEP 1) — survodutide edges standard-dose Wegovy. FDA status: Survodutide is investigational. Wegovy 2.4 mg was approved June 2021 for chronic weight management; in August 2025 it also became the first GLP-1 approved for MASH with moderate-to-advanced fibrosis, based on the ESSENCE trial showing 62.9% vs 34.3% placebo MASH resolution at 72 weeks. Cardiovascular evidence: Wegovy has the SELECT trial (significant reduction in major adverse cardiovascular events). Survodutide has SYNCHRONIZE-CVOT in progress.

Survodutide vs Wegovy HD (semaglutide 7.2 mg) — the comparison most coverage is missing

Mechanism: Wegovy HD is the same molecule as standard Wegovy (semaglutide), at a higher 7.2 mg weekly dose. Phase 3 weight loss: Survodutide 16.6% vs Wegovy HD 20.7% (efficacy estimand) / 18.8% (treatment-regimen estimand) in STEP UP. About 31.2% of Wegovy HD participants achieved at least 25% weight loss. FDA status: Wegovy HD was FDA approved March 19, 2026. It's the natural step-up for people already on standard Wegovy who need more.

Survodutide vs Zepbound (tirzepatide)

Mechanism: Both are dual agonists, but on different second receptors. Survodutide hits GLP-1 + glucagon. Zepbound hits GLP-1 + GIP. Phase 3 weight loss: Survodutide 16.6% vs Zepbound ~20.9% (SURMOUNT-1) and 20.2% (SURMOUNT-5 head-to-head vs semaglutide). Zepbound currently shows the highest mean Phase 3 weight loss in an approved drug. Survodutide's edge — if it materializes — will be the liver/MASH application and possibly a different response for tirzepatide plateaus.

Survodutide vs retatrutide

Mechanism: Retatrutide is a triple receptor agonist — GLP-1 + GIP + glucagon. Phase 2 weight loss: Up to 24.2% at 48 weeks. Phase 3 results not yet published. If you want the absolute highest-efficacy investigational drug, retatrutide is the headliner. If you want the next available next-generation drug, survodutide is likely to reach the U.S. market first.

Survodutide vs Foundayo (orforglipron) and oral Wegovy

If injection avoidance is your priority, you have two FDA-approved oral GLP-1 options as of April 2026: Foundayo (orforglipron) — a daily small-molecule oral GLP-1 from Eli Lilly, approved April 1, 2026, with 12.4% mean weight loss in ATTAIN-1, taken any time of day with or without food. Oral Wegovy (semaglutide 25 mg) — a daily oral version of semaglutide with ~13.6% mean weight loss in OASIS 4. Both are lower mean weight loss than the injectables, but for many people the convenience of a daily pill outweighs the gap.

How does the survodutide weight loss drug actually work?

What GLP-1 does (the part you've heard of)

GLP-1 is a gut hormone. When you eat, your gut releases it. It travels to your brain, signals fullness, and tells your stomach to empty more slowly. Drugs that mimic GLP-1 — semaglutide (Wegovy/Ozempic), tirzepatide (Zepbound/Mounjaro), liraglutide (Saxenda), orforglipron (Foundayo) — all use this pathway. Survodutide is a synthetic 29-amino-acid peptide modified with a fatty acid chain to keep it active for about a week, which is why it's a once-weekly injection.

What the glucagon arm adds (the part that's actually new)

Activating glucagon receptors at sustained, controlled levels has three effects relevant to weight and metabolism:

1. Increases energy expenditure. The body uses more calories at rest.
2. Mobilizes fat from the liver. Glucagon receptors are concentrated in liver tissue, and activation tells the liver to break down stored fat.
3. Reduces hepatic steatosis. This is why survodutide has Breakthrough Therapy designation for MASH.

The catch: glucagon also raises blood sugar. The engineering challenge of survodutide was tuning the GLP-1-to-glucagon ratio so the GLP-1 effect (which lowers blood sugar via insulin) offsets the glucagon effect. Phase 2 and Phase 3 trials suggest the balance works.

Survodutide side effects: what we know and what we're still waiting on

What Phase 2 actually showed

• Nausea (most common, especially during dose escalation)
• Vomiting
• Diarrhea
• Constipation
• Abdominal pain
• Headache, fatigue, dizziness in some participants

The discontinuation rate due to side effects was ~25% in survodutide groups vs ~4% on placebo. The vast majority of those discontinuations happened during the rapid 20-week dose escalation, not during the maintenance phase. Among participants who tolerated escalation, ongoing side effects were typically mild. Serious adverse events were actually slightly lower on survodutide (4.2%) than on placebo (6.5%) in the same trial.

Class-level cautions worth knowing

These are common cautions on approved GLP-1 drug labels. Survodutide's final label is unknown because it isn't approved.

• Pancreatitis — rare but reported with GLP-1s. Persistent severe abdominal pain is a warning sign. See our GLP-1 pancreatitis risk guide.
• Gallbladder issues — rapid weight loss of any kind increases gallstone risk. Reported with multiple GLP-1s.
• Theoretical thyroid C-cell tumor risk — observed in rodent studies for the GLP-1 class. Approved GLP-1s are contraindicated in people with personal or family history of medullary thyroid carcinoma or MEN 2.
• Hypoglycemia — low risk on its own but elevated when combined with insulin or sulfonylureas.

What we don't know yet about survodutide safety

• Long-term cardiovascular outcomes (SYNCHRONIZE-CVOT, years away)
• Long-term cancer risk (no signal yet, but long-term human follow-up doesn't exist)
• Drug-drug interactions in real-world populations
• Pregnancy and lactation safety

What about MASH and fatty liver disease?

The Phase 2 survodutide MASH trial (Sanyal et al., NEJM 2024) randomized 293 adults with biopsy-confirmed MASH and fibrosis stages F1–F3 to weekly survodutide or placebo for 48 weeks. The primary endpoint — improvement in MASH without worsening fibrosis — was met dose-dependently. Phase 3 LIVERAGE and LIVERAGE-Cirrhosis (~1,800 participants combined) are underway.

If MASH/fatty liver is your real concern, here are the legitimate paths today

What can you do today? (The decision matrix)

The right next step depends on what attracted you to survodutide in the first place. Match yourself to the row below.

Match your reason for wanting survodutide to the best approved option available today.

Three specific provider routes

Frequently asked questions about the survodutide weight loss drug

Related guides on The RX Index

• Wegovy HD Insurance Coverage — 2026 cost, PA rules, and $399 self-pay
• Wegovy HD vs Wegovy Pill — formulation comparison
• GLP-1 Pancreatitis Risk — symptoms, FDA label rates, and red flags
• Zepbound Providers That Accept HSA or FSA
• Find My GLP-1 Path quiz — 60-second personalized routing tool

How we built this page (and how to spot-check it)

Source hierarchy we used

1. FDA and regulatory sources — drugs.fda.gov, FDA press announcements, FDA consumer guidance, ClinicalTrials.gov
2. Company primary announcements — Boehringer Ingelheim and Zealand Pharma April 28, 2026 press releases; Novo Nordisk Wegovy HD and MASH announcements; Eli Lilly Foundayo announcement
3. Peer-reviewed clinical literature — Lancet Diabetes Endocrinology (Le Roux et al., 2024 Phase 2 obesity); NEJM (Sanyal et al., 2024 Phase 2 MASH; Jastreboff et al., 2022 SURMOUNT-1; Aronne et al., 2025 SURMOUNT-5; Wilding et al., 2021 STEP 1; Jastreboff et al., 2023 retatrutide Phase 2); STEP UP and ESSENCE trial data
4. Reputable medical and trade media — Reuters, The Wall Street Journal, BioPharma Dive, BioSpace
5. Provider pricing pages — Ro, Sesame, Eden — verified April 28, 2026

What we couldn't verify yet

• Full SYNCHRONIZE-1 safety and granular responder data (coming at ADA June 2026)
• Boehringer's exact NDA submission date for obesity
• Whether Boehringer will request priority review for the obesity submission
• SYNCHRONIZE-2 readout timing
• Future commercial pricing or insurance coverage
• The eventual brand name

Correction policy: If you find a factual error or a source that supersedes one we cited, write to us — we update pages and preserve the “Last verified” timestamp. We re-verify the timeline monthly and immediately on any Boehringer Ingelheim or FDA announcement.

So — wait, switch, or start?